Diabetes, advanced glycation endproducts and vascular disease

Vascular Medicine

Volumn 3, Issue 2, 1998, Pages 131-137

  Wautier, Jean Luc ^a   Guillausseau, Pierre Jean ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

AGE receptors; Angiopathy; Diabetes mellitus; Glycation

Indexed keywords

AMINOGUANIDINE;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HUMAN; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

EID: 0031725628     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9800300207     Document Type: Review

References (71)

1. King GI, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994; 45: 179-88.
2. Maillard LC. Action des acides aminés sur les sucres. Formation des mélanoïds par voie méthodique. CR Acad Sci (France) 1952; 154: 66-68.
3. Brownlee M. Advanced glycation end products in diabetic complications. Curr Opin Endocrinol Diabetes 1996; 3: 291-97.
4. Chappey O, Dosquet C, Wautier MP, Wautier JL. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997; 27: 97-108.
5. Mahley RW, Innerarity TL, Weisgraber KH, Oh SY. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification of lysine residues of the apoprotein B. J Clin Invest 1979; 64: 743-50.
6. Bucala R, Makita Z, Koscjinsky T, Cerami A, Vlassara H. Lipid advanced glycation pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-38.
7. Steinbrecher U, Witztum JL. Glycosylation of low-density lipoproteins on a extent comparable to that seen in diabetes shows their catabolism. Diabetes 1984; 33: 130-34.
8. Hoff HF, Whitaker TE, O'Neil J. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition. J Biol Chem 1992; 267: 602-09.
9. Curtiss LK, Witztum JL. A novel method for generating region specific monoclonal of human glycosylated low density lipoproteins. J Clin Invest 1983; 72: 1427-38.
10. Vlassara H, Brownlee M, Cerami A. High-Affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for a removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5588-92.
11. Gilcrease MZ, Hoover RL. Activated human monocytes exhibit receptor-mediated adhesion to a non-enzymatically glycosylated protein substrate, Diabetologia 1990; 33: 329-33.
12. Imani F, Horii Y, Suthanthiran M et al. Advanced glycosylation end product-specific receptors on human and rat T-lymphocytes mediates synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993; 178: 2165-72.
13. Yang Z, Makita Z, Horii Y et al. Two novel rat liver membrane proteins, that bind advanced glycosylation end products, relationship to macrophage receptor glucose-modified proteins. J Exp Med 1991; 174: 515-24.
14. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 1991; 174: 931-39.
15. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-97.
16. Schmidt AM, Mora R, Cao R et al. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 1994; 269: 9882-88.
17. Neeper M, Schmidt AM, Brett, J et al. Cloning expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
18. Renard C, Chappey O Wautier MP et al. Recombinant advanced glycation end products receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997; 52: 64-62.
19. Sugaya K, Fukagawa T, Matsumoto KT et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, BPX2 homeobox gene and a Notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994; 23: 408-19.
20. Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 1995; 270: 25 752-61.
21. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-28.
22. Vlassara H, Li YM, Imani F et al. Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products (AGE): a new member of the AGE receptor complex. Mol Med 1995; 1: 634-46.
23. McDonald MJ, Shapiro R, Bleichman M et al. Glycosylated minor components of human adult hemoglobin. J Biol Chem 1978; 253: 2327-32.
24. Ratnaikes S, Blake D, Shevenan P. Enzymatic glycation may decrease activity of erythrocyte S-aminolevulinate dehydratase in diabetes mellitus. Clin Chem 1987; 33: 1807-10.
25. Argawak KC, Parks RE, Widenss JA et al. Non enzymatic glycosylation of erythrocytic proteins in normal and diabetic subjects, enzyme of nucleoside and nucleotide metabolism. Diabetes 1985; 34: 251-55.
26. Miller JA, Gravallese E, Bunn HF. Nonenzymatic glycosylation of erythrocyte membrane proteins and membrane fluidity. J Clin Invest 1980; 65 : 896-901.
27. Bryszewska M, Szosland K. Association between glycation of erythrocyte membrane fluidity. Ann Clin Res 1988; 21: 49-51.
28. Watala C, Zawodniak M, Bryszewska M, Novak S. Nonenzymatic protein glycosylation I. Lowered erythrocyte membrane fluidity in juvenile diabetes. Ann Clin Res 1985; 17: 327-30.
29. McMillan DE, Utterback NG, La Puma J. Reduced erythrocyte deformatility in diabetes. Diabetes 1978; 27: 893-901.
30. Inaba M, Maede Y. Correlation between 4.1a/4.1b ratio and erythrocyte life span. Biochem Biophys Acta 1988; 944: 256-64.
31. Wautier JL, Paton CR, Wautier MP et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and their relation to the vascular complications. N Engl J Med 1981; 305: 237-42.
32. Wautier JL, Wautier MP, Schmidt AM et al. Advanced glycation end products (AGE) on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 1994; 91: 7742-46.
33. Jaap AJ, Shore AC, Tooke JE. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycaemia. Diabetologia 1997; 40: 238-43.
34. Wautier J-L, Zoukourian C, Chappey O. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation endproducts blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-43.
35. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-83.
36. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112: 1217-28.
37. Guillausseau PJ, Massin P, Charles MA et al. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study. Diabet Med. 1958; 15: 151-55.
38. Chase HP, Jackson WE, Hoops SL et al. Blood glucose and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989; 261: 1155-60.
39. Beisswenger PJ, Morre LL, Brinck-Johnsen T, Curphey TJ. Increased collagen-like pentosidine levels and AGEs in early diabetic nephropathy. J Clin Invest 1993; 92: 212-217.
40. MacCance DR, Dyer DG, Dunn JA et al. Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus. J Clin Invest 1993; 91: 2470-78.
41. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimenial diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-58.
42. Hammes HP, Brownlee M, Edelstein D, Martin S, Federlin K. Aminoguinidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-35.
43. Hammes HP, Strödter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995; 38: 656-60.
44. Chibber R, Molinatti PA, Wong JSK, Mirlees D, Kohner EM. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes 1994; 43: 758-63.
45. Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM. Toxication of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 1997; 40: 156-64.
46. Tilton RG, Kawamura T, Chang KC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-202.
47. Murata T, Nagai R, Ishibashi T, Inomata H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-69.
48. Stitt AW, Chakravarthy V, Archer DB, Gardiner TA. Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of non enzymatic glycosylation. Diabetologia 1995; 38: 1271-75.
49. Cho HK, Kozu H, Peyman GA, Party GJ, Khoobehi B. The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats. Ophthal Surg 1991; 22: 44-47.
50. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.
51. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
52. Beisswenger PJ, Makita Z, Curphey TJ et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 1995; 44: 824-29.
53. Berg TJ, Bangstad HJ, Torjesen PA, Osterby R, Bucala R, Hanssen KE. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 1997; 46: 661-65.
54. Zidayeh FN, Cohen MP. Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993; 125: 19-25.
55. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11 704-08.
56. Gugliucei A, Bendayan H. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-60.
57. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker U. Advanced glycation end products up-regalate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436-40.
58. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 1992; 29: 2873-77.
59. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums O. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rats. Diabetologia 1995; 38: 387-94.
60. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease. The Framingham Study. Diabetes Care 1979; 2: 120-26.
61. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
62. Uusitupa MD, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non diabetic subjects. Diabetologia 1993; 36: 1175-84.
63. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control; predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-67.
64. Malmberg K, Ryden L, Hamsten A et al. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996: 17: 1337-44.
65. Nakamura Y, Horii Y, Nishino T et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993; 143: 1649-56.
66. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relations between complications to type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314: 403-408.
67. Sims TJ, Rasmussen LM, Oklund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996; 39: 946-51.
68. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 323: 1629-32.
69. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-38.
70. Rumble JR, Cooper MR, Soulis T et al. Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest 1997; 99: 1016-27.
71. Soulis T, Thallas V, Youssef S et al. Advanced glycation end products and their receptor co-localise in fat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-28.